araag2/HINT huggingface dataset:
Clinical trial NCT00035815 (phase 3, status: completed)
Conditions: amyotrophic lateral sclerosis
ICD codes: G12.21
Drugs: insulin like growth factor, type 1, placebo
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria

        Patients entering this study:

          -  Are between the ages of 18-80 years old.

          -  Legal residents of the United States or Canada.

          -  Have a history of a chronic onset of a progressive motor weakness of less than 24
             months duration.

          -  Fulfill El Escorial criteria of probable or definite ALS.

          -  If female, are surgically sterile, two years postmenopausal, or if of child-bearing
             potential, must be using a medically acceptable method of birth control and agree to
             continue use of this method for the duration of the study. Acceptable methods include
             a barrier method with spermicide, oral contraceptives (normal doses are acceptable;
             low dose oral contraceptives or contraceptive implants must be used with a barrier
             method), intrauterine device (IUD), or abstinence. Have a negative pregnancy test.

          -  Are able to comply with protocol requirements.

          -  Can provide written informed consent.

          -  Have a manual muscle testing score of less than 8.

          -  Have a forced vital capacity by pulmonary function testing *60% predicted.

        Exclusion Criteria:

        Patients entering this study will not:

          -  Have any of the following conditions:renal disease (Creatine > 2.0) or other active
             systemic disease

          -  Have any clinically significant abnormalities on the prestudy laboratory evaluation,
             physical examination, ECG, chest x-ray or ophthalmologic exam.

          -  Have any clinically significant medical condition (e.g., within six months of
             baseline, had myocardial infarction, angina pectoris, and/or congestive heart failure)
             that, in the opinion of the investigator, would compromise the safety of patient.

          -  Have Type I or Type II diabetes.

          -  Have a history of cancer including melanoma with the exception of localized skin
             cancers (with no evidence of metastasis, significant invasion, or re-occurrence within
             three years of baseline) and carcinoma in-situ of the cervix (women only).

          -  Have used an investigational drug within 30 days of baseline visit.

          -  Have had a tracheostomy.

          -  Have a Beck's Depression Inventory score * 12.

          -  Have legal residency outside of the United States or Canada.

          -  Be pregnant or breast-feeding.
Clinical trial NCT00706849 (phase 3, status: completed)
Conditions: heterozygous familial hypercholesterolemia, coronary artery disease
ICD codes: E78.01, E78.00, Z83.42, I25.10, I25.110, I25.119, I25.111, I25.118
Drugs: mipomersen sodium, placebo
SMILES: [H]C1(CC([H])(OP(O)(=S)OCC2([H])OC([H])(CC2([H])OP(O)(=S)OCC2([H])OC([H])(CC2([H])OP(O)(=S)OCC2([H])OC([H])(CC2([H])OP(O)(=S)OCC2([H])OC([H])(CC2([H])OP(O)(=S)OCC2([H])OC([H])(CC2([H])OP(O)(=S)OCC2([H])OC([H])(CC2([H])OP(O)(=S)OCC2([H])OC([H])(CC2([H])OP(O)(=S)OCC2([H])OC([H])(CC2([H])OP(O)(=S)OCC2([H])OC([H])(N3C=NC4=C3NC(=N)N=C4O)C([H])(OCCOC)C2([H])OP(O)(=S)OCC2([H])OC([H])(N3C=C(C)C(=N)N=C3O)C([H])(OCCOC)C2([H])OP(O)(=S)OCC2([H])OC([H])(N3C=NC4=C(N)N=CN=C34)C([H])(OCCOC)C2([H])OP(O)(=S)OCC2([H])OC([H])(N3C=C(C)C(=N)N=C3O)C([H])(OCCOC)C2([H])OP(O)(=S)OCC2([H])OC([H])(N3C=C(C)C(=N)N=C3O)C([H])(OCCOC)C2([H])O)N2C=C(C)C(=N)N=C2O)N2C=C(C)C(O)=NC2=O)N2C=C(C)C(O)=NC2=O)N2C=C(C)C(=N)N=C2O)N2C=NC3=C2NC(=N)N=C3O)N2C=C(C)C(O)=NC2=O)N2C=C(C)C(=N)N=C2O)N2C=C(C)C(O)=NC2=O)C([H])(COP(O)(=S)OC2([H])CC([H])(OC2([H])COP(O)(=S)OC2([H])C([H])(COP(O)(=S)OC3([H])C([H])(COP(O)(=S)OC4([H])C([H])(COP(O)(=S)OC5([H])C([H])(COP(O)(=S)OC6([H])C([H])(CO)OC([H])(N7C=NC8=C7NC(=N)N=C8O)C6([H])OCCOC)OC([H])(N6C=C(C)C(=N)N=C6O)C5([H])OCCOC)OC([H])(N5C=C(C)C(=N)N=C5O)C4([H])OCCOC)OC([H])(N4C=C(C)C(O)=NC4=O)C3([H])OCCOC)OC([H])(N3C=C(C)C(=N)N=C3O)C2([H])OCCOC)N2C=NC3=C(N)N=CN=C23)O1)N1C=NC2=C1NC(=N)N=C2O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of Heterozygous Familial Hypercholesterolemia (HeFH)

          -  Diagnosis of Coronary Artery Disease (CAD)

          -  Stable lipid-lowering therapy for 12 weeks

          -  On maximally tolerated statin therapy with at least 1 statin at a dose greater than
             zero, per Investigator judgment

          -  Stable low-fat diet for 8 weeks

          -  Stable weight for 6 weeks

        Exclusion Criteria:

          -  Significant health problems in recent past including heart attack, stroke, coronary
             syndrome, unstable angina, heart failure, significant arrhythmia, orthostatic
             hypotension, uncontrolled hypertension, blood disorders, liver disease, cancer, or
             digestive problems

          -  Receiving apheresis treatment or last apheresis treatment within 8 weeks
Clinical trial NCT00053638 (phase 3, status: completed)
Conditions: hiv infection
ICD codes: Z21
Drugs: efavirenz, tenofovir, abacavir/lamivudine
SMILES: [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C, C[C@H](CN1C=NC2=C1N=CN=C2N)OCP(O)(O)=O, [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C
Eligibility criteria:

        Inclusion criteria:

          -  Participants must be able to provide informed consent.

          -  Have documented HIV-1 infection.

          -  Have not received more than 14 days of prior treatment with antiretroviral drugs.

          -  Meet laboratory test criteria.

          -  Women of childbearing potential must abstain from sexual intercourse or use acceptable
             contraception.

          -  Must be able to take study medications as directed and complete all study visits and
             evaluations during the 48 week study.

        Exclusion criteria:

          -  Enrolled in other HIV treatment studies.

          -  Pregnant or breastfeeding.
Clinical trial NCT00651560 (phase 3, status: completed)
Conditions: hyperlipidemia
ICD codes: E78.2, E78.49, E78.5
Drugs: ezetimibe (+) simvastatin
SMILES: O[C@@H](CC[C@@H]1[C@H](N(C1=O)C1=CC=C(F)C=C1)C1=CC=C(O)C=C1)C1=CC=C(F)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients Who Voluntary Accept To Participate In The Study After Been Informed By The
             Doctor And Signed The Informed Consent Form.

        Exclusion Criteria:

          -  Any Another Kind Of Contraindication For Use Of Statins

          -  Hypersensitivity To Any Of The Active Ingredients

          -  Increased Serum Hepatic Enzymes (Over 3 Times Only)

          -  Patients With Severe Hepatic Insufficiency

          -  Women who are Pregnant or Potentially Pregnant
Clinical trial NCT00712140 (phase 3, status: unknown status)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: parenteral chemotherapy
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed invasive breast cancer

          -  No evidence of metastatic disease

          -  Overexpression of HER2 receptor defined as 3+ or 2+ HER2 positivity measured by
             fluorescent in situ hybridization (FISH) gene amplification

          -  Indication for chemotherapy based on the following clinical and histopathological
             features:

               -  Receiving or scheduled to receive neoadjuvant chemotherapy

                    -  Time between diagnosis biopsy and start date of chemotherapy should be less
                       than 1 month

               -  Receiving or scheduled to receive adjuvant chemotherapy

                    -  Completely resected disease, with negative surgical margins (apart from deep
                       margin if full thickness resection)

                    -  Marginally resected disease and/or positive sentinel nodes allowed provided
                       patients undergo completion of surgery (breast and/or axillary clearance)
                       after chemotherapy

          -  Hormone receptor status known

        PATIENT CHARACTERISTICS:

          -  Menopausal status not specified

          -  ECOG performance status 0-1

          -  Adequate bone marrow, hepatic, and renal function

          -  LVEF normal by ECHO or MUGA

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  No clinically significant cardiac abnormalities

          -  No myocardial infarction within the past 6 months

          -  No uncontrolled or malignant hypertension

          -  No history of atrioventricular arrhythmia and/or congestive heart failure (even under
             medical control), or active second or third degree cardiac block

          -  No history of allergy to drugs containing polysorbate 20 and the excipient polysorbate
             80 (TWEEN 80®) or history of allergy to mouse proteins

          -  No co-morbidity significantly adding to risks associated with cytotoxic chemotherapy
             (i.e., severe chronic obstructive pulmonary disease or poorly controlled diabetes)

          -  No prior diagnosis of malignancy unless managed by surgical treatment only and
             disease-free for 10 years

               -  Prior basal cell carcinoma, cervical carcinoma in situ, or ductal carcinoma in
                  situ of the breast allowed if treated by surgery only

          -  No concomitant medical or psychiatric problems that might preclude completion of
             treatment or follow-up

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No prior chemotherapy or radiotherapy

          -  Concurrent radiotherapy allowed
Clinical trial NCT00632736 (phase 3, status: completed)
Conditions: parkinson disease, parkinson's disease
ICD codes: G20, G20
Drugs: ropinirole xl (formerly cr)
SMILES: CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1
Eligibility criteria:

        Inclusion Criteria:

        A subject will be eligible for inclusion in this study only if all of the following
        criteria apply:

          -  Subjects must have completed REQUIP studies 165 or 168, or must have completed at
             least 12 weeks of randomised treatment in study 169 (and must have completed the
             one-week down titration at the end of treatment/early withdrawal).

          -  Subjects must not have a break in medication between completing the feeder study
             (including the down titration phase for studies 168 and 169) and beginning treatment
             in study 248.

          -  Women of child-bearing potential must be practicing a clinically accepted method of
             contraception during the study and for one month following completion of the study.
             Acceptable contraceptive methods include oral contraception, surgical sterilization,
             intrauterine device (IUD), or diaphragm IN ADDITION to spermicidal foam and condom on
             male partner, or systemic contraception (e.g. Norplant System).

          -  Provide written informed consent for this study.

          -  Be willing and able to comply with study procedures.

        Exclusion Criteria:

        A subject will not be eligible for inclusion in this study if any of the following criteria
        apply:

          -  Patients with any ongoing clinically significant adverse events at the end of the
             "feeder" studies.

          -  Subjects with severe, clinically significant condition(s) other than Parkinson's
             disease which, in the opinion of the investigator, would render the subject unsuitable
             for the study (e.g., psychiatric, hematological, renal, hepatic, endocrinology,
             neurological (other than Parkinson's disease), cardiovascular, or active malignancy
             (other than basal cell carcinoma).

          -  Subjects with clinically significant abnormalities in Laboratory or ECG tests at the
             end of the feeder study (REQUIP study 165, 168 or 169).

          -  Subjects with severe dizziness or fainting due to postural hypotension on standing.

          -  Withdrawal, introduction, or change in dose of hormone replacement therapy and/or any
             drug known to substantially inhibit cytochrome P 450 1A2 (CYP1A2 [e.g. ciprofloxacin,
             fluvoxamine, cimetidine, ethinyloestradiol]) or induce CYP1A2 (e.g. tobacco,
             omeprazole) within 7 days prior to enrolment. Subjects already on chronic therapy with
             any of these agents may be enrolled but doses must have remained stable from 7 days
             prior to enrolment through the end of the treatment period.

          -  Women who are pregnant or breast-feeding.

          -  Use of an investigational drug throughout the treatment period.
Clinical trial NCT00060671 (phase 3, status: terminated)
Conditions: lymphoma, follicular, lymphoma, mixed-cell, follicular, lymphoma, small cleaved-cell, follicular, lymphoma, low-grade
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: rituximab, pixantrone (bbr 2778)
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, NCCNC1=CC=C(NCCN)C2=C1C(=O)C1=C(C=NC=C1)C2=O
Eligibility criteria:

        Inclusion criteria:

          -  Patients with relapsed or refractory indolent non-Hodgkin's lymphoma (NHL), including
             follicular lymphoma grade I and II

          -  Presenting with an episode of progressive disease, following 1-5 prior treatments
             (with either radiation, chemotherapy or rituximab).

        Exclusion criteria:

          -  Patients that failed to respond to previous rituximab treatment, or relapsed within 6
             months of the first rituximab infusion

          -  Patients known to have an allergic reaction to rituximab or murine derived proteins.
Clinical trial NCT00345839 (phase 3, status: completed)
Conditions: secondary hyperparathyroidism, chronic kidney disease
ICD codes: E21.1, N25.81, I12.9, N18.9, I12.0, D63.1, N18.1, N18.5, I13.0
Drugs: cinacalcet, placebo
SMILES: C[C@@H](NCCCC1=CC(=CC=C1)C(F)(F)F)C1=CC=CC2=CC=CC=C12, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Inclusion:≥ 18 years of age

          -  Treated with maintenance hemodialysis - PTH ≥ 300 pg/mL (31.8 pmol/L)

          -  serum calcium ≥ 8.4mg/dL (2.1 mmol/L)

          -  Ca x P ≥ 45 mg2*/dL2 (3.63 mmol2/L2)

        Exclusion Criteria: - Exclusion:

          -  Parathyroidectomy in the 12 weeks before the date of informed consent

          -  Received therapy with cinacalcet within 3 months of randomization

          -  Hospitalization within 12 weeks of randomization for any of the following events: a.
             Myocardial ischemia b. Unstable angina c. Heart Failure (HF) (including any unplanned
             presentation to a health care facility that would require mechanical intervention
             [i.e., unplanned dialysis treatment]) d. Peripheral vascular disease (other than
             dialysis vascular access revision) e. Stroke

          -  History of seizure within 12 weeks prior to randomization

          -  Scheduled date for kidney transplant from a known living donor

          -  Anticipated parathyroidectomy within 6 months after randomization

               -  in all instances, the 2 refers to squared.
Clinical trial NCT01034163 (phase 3, status: completed)
Conditions: hodgkin's lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: panobinostat, placebo
SMILES: [H]\C(=C(\[H])C1=CC=C(CNCCC2=C(C)NC3=CC=CC=C23)C=C1)C(O)=NO, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Patient age is greater than or equal to 18 years

          2. Patient has a history of histologically confirmed classical HL (i.e. Nodular
             sclerosing (NSHL), Mixed-cellularity (MCHL), Lymphocyte-rich (LRHL), Lymphocyte
             depleted (LDHL))

          3. Patient has achieved a complete response by CT/MRI scan within 9 weeks (± 1 week) from
             the day of their first autologous peripheral blood/ bone marrow stem cell transfusion
             (AHSCT) following HDT. Complete response is defined as:

             Normalization of all nodes and lesions compared to pre-transplant scan performed prior
             to salvage therapy for relapse. Any residual abnormal masses on the post transplant
             CT/MRI must be metabolically inactive on a PET scan.

          4. Patient has at least one of the following factors that places them at risk for
             relapse:

               -  Primary refractory disease (including relapse in ≤ 3 months of completion of 1st
                  line treatment)

               -  First relapse >3 but <12 months from last dose of 1st line treatment

               -  Multiple relapses (prior to transplant)

               -  Stage III/IV disease (at relapse, prior to transplant)

               -  Hemoglobin <10.5 gm/dL (at relapse, prior to transplant)

        Exclusion Criteria:

        Patient has been treated with allogeneic transplant 2. Patient has received any
        anti-lymphoma therapy after AHSCT including but not limited to:

          -  chemotherapy prior to start of study

          -  biologic immunotherapy including monoclonal antibodies or experimental therapy prior
             to start of study

          -  radiation therapy 3. Patient has not recovered from reversible toxicity due to any
             prior therapies (e.g. returned to baseline or Grade ≤1) except for hematological
             laboratory parameters Note: Patient does not meet this criteria if the toxicity is
             stable and irreversible, and there is no evidence that panobinostat causes a similar
             toxicity 4. Patient has received prior treatment with DAC inhibitors including
             panobinostat
Clinical trial NCT00449111 (phase 3, status: terminated)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: mk0954, losartan potassium / duration of treatment - 12 weeks
SMILES: CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1
Eligibility criteria:

        Inclusion Criteria:

          -  Patient treated with valsartan 80mg or irbesartan 150mg or vandesartan 8mg for at
             least 4 weeks prior to visit 1

          -  Patient with systolic blood pressure between 140 to 159 mmhg and diastolic pressure
             between 90 to 99mmhg taken at visit 1

        Exclusion Criteria:

          -  History of angina pectoris that has not been stabilized in the past 6 weeks

          -  History of clinically significant abnormal lab results or diseases

          -  Myocardial infarction within the past 6 months

          -  Stroke in the past 6 months
Clinical trial NCT00055679 (phase 3, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: cyclophosphamide, epirubicin hydrochloride, fluorouracil
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed nonmetastatic, unilateral adenocarcinoma of the breast

               -  Stage I

               -  No clinically or radiologically suspicious metastases

               -  No positive sentinel lymph nodes by immunohistochemistry for tumors less than 2
                  cm

               -  No clinically proven positive axillary lymph nodes

                    -  Tumor cells found on immunohistochemistry only allowed

               -  No clinically or radiologically contralateral suspicious lesions

          -  No deeply adherent disease

          -  No cutaneous invasion

          -  No inflammatory disease

          -  Complete surgical resection within the past 42 days

               -  At least 8 lymph nodes removed

          -  Tumor at least 1 cm with no residual disease

          -  Presenting with at least 1 of the following factors of a poor prognosis:

               -  Tumor greater than 2 cm

               -  Hormone receptor negative tumor

               -  Grade II or III

               -  35 years old or under

          -  Hormone receptor status:

               -  Positive or negative

        PATIENT CHARACTERISTICS:

        Age

          -  18 to 65

        Sex

          -  Female

        Menopausal status

          -  Not specified

        Performance status

          -  WHO 0-1

        Life expectancy

          -  Not specified

        Hematopoietic

          -  WBC at least 2,000/mm^3

          -  Platelet count at least 100,000/mm^3

        Hepatic

          -  Bilirubin no greater than 1.25 times upper limit of normal (ULN)

          -  AST and ALT no greater than 1.25 times ULN

          -  Alkaline phosphatase no greater than 2.5 times ULN

          -  No chronic hepatitis B

          -  No active hepatitis C

        Renal

          -  Creatinine no greater than 1.25 times ULN

        Pulmonary

          -  FEV normal

        Other

          -  Not pregnant or nursing

          -  HIV negative

          -  No prior breast cancer or other malignancy

          -  No familial, social, or geographical reason that would preclude study participation

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  No prior chemotherapy

        Endocrine therapy

          -  No prior anticancer hormone therapy

        Radiotherapy

          -  No prior radiotherapy

        Surgery

          -  See Disease Characteristics
Clinical trial NCT00102388 (phase 3, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: vildagliptin, gliclazide
SMILES: CN(C)C(=N)NC(N)=N, CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN1CC2CCCC2C1
Eligibility criteria:

        Inclusion Criteria:

          -  Not currently on drug therapy for type 2 diabetes

          -  Body mass index (BMI) in the range 22-45

          -  Blood glucose criteria must be met

        Exclusion Criteria:

          -  Pregnancy or lactation

          -  Type 1 diabetes

          -  Evidence of significant diabetic complications

          -  Evidence of serious cardiovascular conditions

          -  Laboratory value abnormalities as defined by the protocol

          -  Other protocol-defined exclusion criteria may apply